Value of color Doppler ultrasound in the treatment of recurrent melanoma with isolated limb perfusion
暂无分享,去创建一个
S. Bonvalot | N. Lassau | M. Avril | J. Leclère | S. Bidault | P. Hochedez
[1] F. Lejeune,et al. In transit metastases of malignant melanoma treated by high dose rTNFα in combination with interferon-γ and melphalan in isolation perfusion , 1992, World Journal of Surgery.
[2] B. S. B. John F. Thompson M.B.,et al. Isolated limb perfusion for melanoma: Effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs , 2005, World Journal of Surgery.
[3] A. Padhani,et al. The RECIST criteria: implications for diagnostic radiologists , 2001 .
[4] W. Sterry,et al. Efficacy of ultrasound B‐scan compared with physical examination in follow‐up of melanoma patients , 2001, Cancer.
[5] A. Blum,et al. Ultrasound examination of regional lymph nodes significantly improves early detection of locoregional metastases during the follow‐up of patients with cutaneous melanoma , 2000, Cancer.
[6] S. Koscielny,et al. New hemodynamic approach to angiogenesis: color and pulsed Doppler ultrasonography. , 1999, Investigative radiology.
[7] S. Koscielny,et al. Prognostic value of high-frequency sonography and color Doppler sonography for the preoperative assessment of melanomas. , 1999, AJR. American journal of roentgenology.
[8] D. Vanel,et al. Value of high-frequency US for preoperative assessment of skin tumors. , 1997, Radiographics : a review publication of the Radiological Society of North America, Inc.
[9] P. Kam,et al. Frequency and duration of remission after isolated limb perfusion for melanoma. , 1997, Archives of surgery.
[10] A. Eggermont,et al. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs. , 1996, Journal of the American College of Surgeons.
[11] G. Balderson,et al. Hyperthermic isolated limb perfusion for malignant melanoma: Response and survival , 1995, World journal of surgery.
[12] A. Eggermont,et al. Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study. , 1994, Melanoma research.
[13] A. Hart,et al. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. , 1994, Surgery.
[14] J. Thomas,et al. Treatment of cutaneous metastases from malignant melanoma using the carbon-dioxide laser. , 1993, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[15] R. Mirimanoff,et al. Regional therapy of melanoma. , 1993, European journal of cancer.
[16] S. Carlini,et al. Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion , 1989, Cancer.
[17] C. Karakousis,et al. Prognostic parameters in recurrent malignant melanoma , 1983, Cancer.
[18] E. V. van Slooten,et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. , 1982, European journal of cancer & clinical oncology.
[19] R. F. Ryan,et al. Chemotherapy of Cancer: Regional Perfusion Utilizing an Extracorporeal Circuit , 1958, Annals of surgery.